However, PCSK9 inhibitors may be justified in select high-risk patients who are either statin-intolerant or unable to achieve LDL-C targets despite maximal statin therapy, especially those with FH or diabetes [25]. This evidence concerns the gene PCSK9 and familial hyperaldosteronism.